NCT00268710View on ClinicalTrials.gov

Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Prostatic Neoplasms
Interventions
DRUG

docetaxel

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Canadian Urologic Oncology Group

OTHER

lead

Sanofi

INDUSTRY

NCT00268710 - Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC] | Biotech Hunter | Biotech Hunter